<DOC>
	<DOCNO>NCT00268229</DOCNO>
	<brief_summary>RATIONALE : Imatinib mesylate may stop growth cancer cell block enzymes need cell growth . Drugs use chemotherapy , daunorubicin cytarabine , work different way stop growth cancer cell , either kill cell stop divide . Giving imatinib mesylate together daunorubicin cytarabine may kill cancer cell . PURPOSE : This phase I trial study side effect best dose imatinib mesylate give together daunorubicin cytarabine treat patient relapse acute myeloid leukemia .</brief_summary>
	<brief_title>Imatinib Mesylate , Daunorubicin , Cytarabine Treating Patients With Relapsed Acute Myeloid Leukemia</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine maximum tolerate dose ( MTD ) recommend phase II dose imatinib mesylate combination daunorubicin hydrochloride cytarabine patient relapse acute myeloid leukemia . Secondary - Assess non-dose-limiting toxicity associate regimen patient . - Determine preliminary evidence clinical activity regimen patient . OUTLINE : This open-label , dose-escalation study imatinib mesylate . Patients receive daunorubicin IV day 1-3 cytarabine IV continuously day 1-7 . Patients also receive oral imatinib mesylate daily begin day 1 continue disease progression unacceptable toxicity . Patients persistent leukemia day 14 bone marrow biopsy ≥ 50 % reduction bone marrow blast receive 5 day cytarabine 2 day daunorubicin continue imatinib mesylate . Cohorts 3-6 patient receive escalate dos imatinib mesylate maximum tolerate dose ( MTD ) determine . The MTD define dose precede 1 3 2 6 patient experience dose-limiting toxicity . At least 6 patient treated MTD . After completion study treatment , patient follow periodically . PROJECTED ACCRUAL : A total 24 patient accrue study .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Bone marrow biopsy confirm acute myeloid leukemia ( AML ) No M3 AML Patient must relapse standard chemotherapy Patients relapse within six month response treatment never respond anthracycline/cytarabine combination exclude At least 20 % peripheral blood bone marrow blast positive ckit No evidence leptomeningeal involvement PATIENT CHARACTERISTICS : ECOG Performance Status 02 Liver enzyme ( AST ALT ) total bilirubin ≤ 2 time upper limit normal Serum creatinine ≤ 2 time upper limit normal No New York Heart Association grade III IV cardiac problem Defined congestive heart failure myocardial infraction within past 6 month No know chronic liver disease ( i.e. , chronic active hepatitis cirrhosis ) No serious poorly control medical condition could exacerbate treatment would seriously complicate compliance study No active primary malignancy unless currently clinically significant require active intervention No history HIV infection Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 3 month completion study treatment No significant history noncompliance medical regimen inability grant reliable informed consent PRIOR CONCURRENT THERAPY : Previous treatmentrelated toxicity resolve No investigational agent within past 28 day No chemotherapy within past 4 week 6 week nitrosourea mitomycin C No major surgery within past 4 week No concurrent use follow drug allow : ketoconazole , dilantin , itraconazole , erythromycin , clarithromycin , dexamethasone , rifampin , tegretol , phenobarbital , Hypericum perforatum ( St. John 's wort ) , cyclosporine , pimozide , warfarin , certain HMGCoA reductase inhibitor , traizolobenzodiazepines , dihydropyridine calcium channel blockers No concurrent anticancer agent , include chemotherapy biologic agents No concurrent investigational drug Concurrent medication know metabolized cytochrome p450 enzyme allow No therapeutic anticoagulation warfarin permit patient participate study Therapeutic anticoagulation may accomplish use lowmolecular weight heparin Minidose warfarin prophylaxis central venous catheter thrombosis allow No concurrent routine use systemic corticosteroid therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>adult acute minimally differentiate myeloid leukemia ( M0 )</keyword>
	<keyword>adult acute megakaryoblastic leukemia ( M7 )</keyword>
	<keyword>adult acute monoblastic leukemia ( M5a )</keyword>
	<keyword>adult acute monocytic leukemia ( M5b )</keyword>
	<keyword>adult acute myeloblastic leukemia maturation ( M2 )</keyword>
	<keyword>adult acute myeloblastic leukemia without maturation ( M1 )</keyword>
	<keyword>adult acute myelomonocytic leukemia ( M4 )</keyword>
	<keyword>adult erythroleukemia ( M6a )</keyword>
	<keyword>adult pure erythroid leukemia ( M6b )</keyword>
</DOC>